Category: 259231-26-0

On January 1, 2016, Ma, Zhihua; Lin, Daniel C.-H.; Sharma, Rajiv; Liu, Jinqian; Zhu, Liusheng; Li, An-Rong; Kohn, Todd; Wang, Yingcai; Liu, Jiwen; Bartberger, Michael D.; Medina, Julio C.; Zhuang, Run; Li, Frank; Zhang, Jane; Luo, Jian; Wong, Simon; Tonn, George R.; Houze, Jonathan B. published an article.Recommanded Product: 2-Bromo-4-(bromomethyl)-1-methylbenzene The title of the article was Discovery of the imidazole-derived GPR40 agonist AM-3189. And the article contained the following:

As a follow-up to the GPR40 agonist AMG 837, which was evaluated in clin. trials for the treatment of type II diabetes, further optimization led to the discovery of AM-3189 I. I is representative of a new class of compounds with minimal CNS penetration, superior pharmacokinetic properties and in vivo efficacy comparable to AMG 837. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Recommanded Product: 2-Bromo-4-(bromomethyl)-1-methylbenzene

The Article related to preparation imidazole gpr agonist antidiabetic diabetes, am-3189, amg 837, agonist, ffar1, gpcr, gpr40, insulin secretagogue, type ii diabetes, Pharmacology: Structure-Activity and other aspects.Recommanded Product: 2-Bromo-4-(bromomethyl)-1-methylbenzene

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On November 29, 2001, Astles, Peter C.; Eastwood, Paul R.; Houille, Olivier; Levell, Julian; Pauls, Heinz; Czekaj, Mark; Liang, Guyan; Gong, Yong; Pribish, James; Neuenschwander, Kent published a patent.Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene The title of the patent was Preparation of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors. And the patent contained the following:

Title compounds I [Ar = (hetero)aryl, where the two groups on the Ar ring are β to each other; R1-2 = H, alkyl; R3 = (un)substituted(hetero)aryl, arylalkenyl, cycloalkenyl, cycloalkyl, etc.; R4 = H, acyl, alkoxy, alkyloxycarbonyl, carboxy, CN, halo, etc.; n = 0 – 4] were prepared Over 300 synthetic examples were disclosed. For instance, 3-bromobenzylbromide was converted in two steps to boronate II. II was coupled to the triflate ester derivative of the enol of 4-oxo-N-benzyloxycarbonylpiperidine (DMF, K2CO3, PdCl2(dppf)•CH2Cl2, 80°C, 18 h) to give the corresponding bicyclic intermediate. This intermediate was deprotected and reduced to the piperidine (EtOH, 10% Pd-C/H2, room temperature, 5 h) and coupled to 5-phenethylthiophene-2-carboxylic acid (DMF, HAPyU, iPr2NEt, room temperature, 18 h) to give III. III had Ki = 50 nM for tryptase. I are useful in the treatment of e.g., asthma and inflammatory diseases. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene

The Article related to piperidinylbenzylamine tryptase inhibitor preparation, pyridine quinoline thiophene furan indole piperidine tryptase inhibitor preparation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 29, 2018, Zhu, Bin published a patent.Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene The title of the patent was Microglial cell IL-1β secretion inhibitor, and its preparation method and application in treatment of neuroinflammatory diseases. And the patent contained the following:

The title microglial cell IL-1β secretion inhibitor is (((2,5-dibromocyclopenta-2,4-diene-1,1-diyl)bis(methylene))bis(6-alkyl-3,1-phenylene))diboronic acid, has structural formula shown as formula I in Claim 1, wherein R is C1-C10 alkyl or C3-C8 cycloalkyl. The invention also provides preparation method of above compound from cyclopenta-1,3-diene, 2-bromo-4-(bromomethyl)-1-alkylbenzene, boric acid, and bromine. The invention also provides application of the microglial cell IL-1β secretion inhibitor in preparation of drugs for treatment of neuroinflammatory diseases. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene

The Article related to bromocyclopenta dienediyl diboronic acid preparation neuroinflammatory disease treatment, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Name: 2-Bromo-4-(bromomethyl)-1-methylbenzene

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 21, 2022, Yang, Dun; Zhang, Jing; Zhang, Shenqiu; Allen, Thaddeus; Shi, Qiong; Nimishetti, Naganna; Huang, Jian; Li, Hongmei; Yang, Chenglu published a patent.Related Products of 259231-26-0 The title of the patent was Preparation of fused azepine compounds and their use in the treatment of cancer. And the patent contained the following:

The invention relates to fused azepines of formula I and pharmaceutically acceptable salts thereof; their preparation and use in the treatment of cancer. Compounds of formula I, wherein X is O and S; ring A is (un)substituted Ph, (un)substituted 6-membered heteroaryl; L is a bond, CO, SO2, etc.; each R1 is independently halo, CN, (un)substituted Ph, etc.; each R2 is H, CN, (un)substituted Ph, etc.; each R3 is (un)substituted Ph, (un)substituted heteroaryl, (un)substituted 3- to 7-membered carbocyclyl, etc.; m = 0 – 4; p = 0 – 5; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by condensation of Me 5-hydroxy-2-oxo-2,3-dihydro-1H-benzo[b]azepine-4-carboxylate with (bromomethyl)benzene. The invention compounds were evaluated for their anticancer activities (some data given). The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Related Products of 259231-26-0

The Article related to fused azepine treatment cancer preparation, Heterocyclic Compounds (One Hetero Atom): Higher-Membered Rings and other aspects.Related Products of 259231-26-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On September 2, 2005, Chow, Hak-Fun; Low, Kam-Hung; Wong, King Y. published an article.Safety of 2-Bromo-4-(bromomethyl)-1-methylbenzene The title of the article was An improved method for the regiospecific synthesis of polysubstituted [2.2]paracyclophanes. And the article contained the following:

4,16-Disubstituted, 4,7,12,15-tetrasubstituted, 4,8,12,16-tetrasubstituted and 4,5,7,8,12,13,15,16-octasubstituted [2.2]paracyclophanes can be prepared in significantly improved yields and excellent regiospecificities via the Winberg 1,6-elimination-dimerization reaction from substituted (4-methylbenzyl)trimethylammonium hydroxides. Using 2-chlorophenothiazine instead of phenothiazine as a polymerization inhibitor results in a doubling of product yields. The crystal structures of two of the products are available online. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Safety of 2-Bromo-4-(bromomethyl)-1-methylbenzene

The Article related to paracyclophane preparation crystal structure, bromoparacyclophane preparation crystal structure, methylbenzylmethylammonium hydroxide preparation winberg elimination dimerization and other aspects.Safety of 2-Bromo-4-(bromomethyl)-1-methylbenzene

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 22, 1999, Stolle, Andreas; Antonicek, Horst-Peter; Lensky, Stephen; Voerste, Arnd; Muller, Thomas; Baumgarten, Jorg; Von Dem Bruch, Karsten; Muller, Gerhard; Stropp, Udo; Horvath, Ervin; De Vry, Jean-Marie Viktor; Schreiber, Rudy published a patent.SDS of cas: 259231-26-0 The title of the patent was Preparation of 6-benzyl-5-methylidenehexahydrocyclopenta[c]furan-1-ones as metabotropic glutamate receptor modulators.. And the patent contained the following:

Title compounds [I; A = CH2, CO, CR4OH, (CH2)aCHR5, alkylene, alkenylene, alkynylene; a = 0-4; R4 = H, alkyl; R5 = Ph; R1 = H, (substituted) cycloalkyl, heterocyclyl, benzoheterocyclyl, aryl, etc.; R2, R3 = H, alkyl; DE = CH2C(:CR32R31)CH2, CR33:CR34CHR35, etc.; R31-R35 = H, Ph, alkyl], were prepared for preventing and/or treating diseases caused by the hyper- or hypofunction of the glutamatergic system, especially cerebral ischemia, cranial/cerebral trauma, pain or CNS-mediated cramps (no data). Thus, 2-methoxycarbonyl-4-methylidenecyclopentanecarboxylic acid in THF at -15° was treated with Et3n and EtO2CCl followed by 1 h stirring at room temperature The mixture was filtered and the filtrate in MeOH at -15° was treated with NaBH4 followed by 1 h stirring at room temperature to give 58% (3aS*,6aR*)-5-methylidenehexahydrocyclopenta[c]furan-1-one. The latter in PhMe was was added to LiN(SiMe3)2 in THF/PhMe at -78° followed by warming to room temperature, 1 h stirring, and addition of PhCH2Br to give 68% (3aS*,6aR*)-6a-benzyl-5-methylidenehexahydrocyclopenta[c]furan-1-one. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).SDS of cas: 259231-26-0

The Article related to benzylmethylidenehexahydrocyclopentafuranone preparation metabotropic glutamate receptor modulator, cyclopentafuranone benzyl methylidene preparation metabotropic glutamate receptor modulator, analgesic benzylmethylidenehexahydrocyclopentafuranone, head trauma treatment benzylmethylidenehexahydrocyclopentafuranone and other aspects.SDS of cas: 259231-26-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary